Know What's Happening in Industry

Medtronic’s RDN System Receives New Reimbursement Approval

Medtronic’s Symplicity Spyral renal denervation system has secured reimbursement approval from Japan’s Ministry of Health, Labour and Welfare, expanding coverage for resistant hypertension. The therapy, which uses radio‑frequency energy to ablate renal nerves via a single catheter, was previously approved in Japan in September 2025 and is already marketed in roughly 80 countries. The decision follows FDA clearance in 2023 and national Medicare coverage in the United States, reflecting growing clinical acceptance. With hypertension affecting an estimated 43 million Japanese adults, the reimbursement move is poised to increase patient access and drive volume for the device.